{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:10:14Z","timestamp":1790208614044,"version":"4.1.0"},"reference-count":19,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/13543784.2026.2656430","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:05:37Z","timestamp":1775225137000},"page":"253-256","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Clinical development of a CDK8\/19 kinase inhibitor for acute myeloid leukemia"],"prefix":"10.1080","volume":"35","author":[{"given":"Akhil","family":"Rajendra","sequence":"first","affiliation":[{"name":"University Health Network","place":["Toronto, Canada"]},{"name":"The Ottawa Hospital","place":["Ottawa, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W. L.","family":"Yee","sequence":"additional","affiliation":[{"name":"University Health Network","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21873"},{"key":"e_1_3_3_4_1","volume-title":"Surveillance research program, National Cancer Institute","year":"2025","unstructured":"SEER*Explorer: an interactive website for seer cancer statistics [internet]. In: Surveillance research program, National Cancer Institute. 2025 Apr 16 [updated 2026 Jan 8; cited 2026 Apr 24]. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2024 Submission (1975\u20132022), SEER 21 registries (excluding Illinois). Expected Survival Life Tables by Socio-Economic Standards."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14904"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02080-z"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118287"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.05.006"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28305"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16810"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.702"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844688.25652.68"},{"key":"e_1_3_3_13_1","first-page":"1008","article-title":"RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed\/refractory AML and higher-risk MDS: preliminary results from two ongoing studies","volume":"8","author":"Chraniuk D","year":"2024","unstructured":"Chraniuk D, Lech-Maranda E, Abboud C, et al. RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed\/refractory AML and higher-risk MDS: preliminary results from two ongoing studies. Hemasphere. 2024;8:1008\u20131009.","journal-title":"Hemasphere"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3424"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.64898\/2025.12.16.693978"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01951"},{"key":"e_1_3_3_17_1","article-title":"Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML","author":"Mohanty V","year":"2024","unstructured":"Mohanty V, Baran N, Huang Y, et al. Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML. bioRxiv. 2024.","journal-title":"bioRxiv"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186620"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70148"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0256"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204168"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2656430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:38:31Z","timestamp":1775817511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2656430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/13543784.2026.2656430"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2656430","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}